Mankind Pharma Ltd. Share Price

Mankind Pharma Slips Below Key Trend Averages

Pre Market Report & Global Cues| 08 September

Global cues are mixed this morning. US markets were closed due to Labour Day, so there is no fresh direction from the US side. At the same time, US 10Y yield is around 4.79%, still on the higher side. Crude is the main concern. Brent is near $97 and holding at higher levels. This is negative for our market as it puts pressure on inflation and the rupee. Asian markets are mixed. Kospi is up nearly 2%, Shanghai and Nikkei are slightly positive, but Hang Seng and Straits Times are in red. Because of this, Gift Nifty is indicating a flat opening. On the domestic side: India 10Y yield is around 6.96% (slightly lower) Rupee is near 94.5, still weak overall Nifty closed at 23,779 in the last session and continues to look a bit weak. There will be stock-specific action today. 1. Adani Power is in focus after approval for a 330 MW hydro project. 2. GE Vernova T&D India may see interest as L1 bidder for a 6,000 MW HVDC project. 3. Garuda Construction has signed a deal with ₹1,800 Cr potential. 4. Defence stocks like BEL, BEML and Paras Defence may stay strong after approval of ₹1.1 lakh Cr defence deals. SBI and Bank of Baroda will also be watched due to developments around the expected NSE IPO. On the weaker side: 1. PVR Inox may see some reaction. 2. Mankind Pharma is in focus due to subsidiary-related news. From sector side: 1. Defence and power look strong 2. IT may stay under pressure 3. Aviation and paints may remain weak due to high crude Today's View: Market is likely to open flat. Crude near $97 is the key issue right now. If Nifty fails to move above 24,000, selling pressure can continue. For any stable move, we need support either from global markets or cooling crude prices.

Mankind Pharma Exits Non-Core Hospitality Business

Mankind Pharma Limited has completed the 100% divestment of its stake in Broadway Hospitality Services Private Limited to AKRK Projects LLP for a cash consideration of ₹49 crore, effective August 31, 2026. Key Highlights: Minimal Financial Impact: The divested entity contributed only ₹9.63 crore (0.07%) to FY26 revenue and held a net worth of ₹38.99 crore (0.24% of Mankind’s total), making this a highly immaterial transaction for the parent company's financials. Complete Exit: Broadway Hospitality ceases to be a subsidiary, marking Mankind Pharma's total withdrawal from the non-core leisure and hospitality sector. Strategic Rationale: Portfolio Rationalization: This move aligns with management’s stated strategy to shed peripheral assets and sharpen the company's focus on high-margin pharmaceutical manufacturing, R&D, and core healthcare operations. Management Bandwidth: The operational cleanup frees up management focus and capital, which is currently critical for the seamless integration of recent large-scale strategic acquisitions, such as Bharat Serums and Vaccines. Outlook: This divestment is a clean, positive step for corporate governance and capital allocation. By eliminating non-core business lines, Mankind Pharma reinforces its identity as a pure-play pharmaceutical major, optimizing its corporate structure for sustained, focused growth in the domestic and global healthcare markets.

Mankind Pharma sells 100% stake in Broadway Hospitality

Mankind Pharma has sold its 100% stake held in Broadway Hospitality Services (Broadway) to AKRK Projects LLP and its Partners. Post this transaction, Broadway has ceased to be a wholly owned subsidiary of the company with effect from August 31, 2026. Earlier, the Board of Directors of the company, at its meeting held on July 11, 2026, had approved the divestment of 100% stake held in Broadway for a consideration of Rs 49.00 crore. Mankind Pharma is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. Mankind is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory.

Mankind Pharma Ltd Mixed Technical Signals

**